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Sex-steroid hormones are a major determinant of the risk of breast cancer. We 
evaluated the relationship between obesity and endogenous estrogen levels in 79 
healthy, postmenopausal women. Thirty-nine of the women were siblings of 
patients with postmenopausal-onset breast cancer; the remaining women were age- 
matched (+ 10 yr) controls. Our hypothesis was that the siblings of the breast 
cancer patients would weigh more and that this excess weight would lead to higher 
serum estrone levels. The choice of unaffected family members of breast cancer 
patients reduces the concern that results may have been influenced by the cancer 
rather than antecedent to its development. Our findings demonstrated a statistically 
significant excess estrone level in the siblings compared to the controls (58.9 vs 
47.8 pg/ml, P=O.OOS). The siblings weighed 4.3 kg more than the controls. 
Matched pairs analysis (sibling -control), adjusting for weight, also showed 
significant differences in serum estrone levels. These differences were observed 
despite comparability in dietary intake, medication use, and personal medical 
history. These findings represent the first time that higher estrogen levels have 
been measured in siblings of postmenopausal breast cancer patients. This obser- 
vation may represent an important link in our understanding of the relationship 
between genetic and environmental risk factors of breast cancer. One approach to 
subsequent genetic studies of breast cancer may be to focus on the possible 
biological determinants such as sex-steroid hormone level receptors, oncogenes, 
and gene products and not on the “familial aggregation” of breast cancer. 
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INTRODUCTION 
The etiology of breast cancer is acknowledged to be multifactorial [MacMahon 
et al, 1973; Kelsey, 19791. Some of the risk factors are classified as environmentally 
related while others are considered to have a genetic predisposition [deWaard, 19731. 
Three of the most commonly cited risk factors are fat intake, obesity, and 
endogenous estrogens and other hormones [Kelsey, 19791. The familial aggregation 
of cases has been recognized since the late 1800s [Miller, 19791. Virtually all reports 
confirm this finding regardless of their country of origin or study design [Lynch, 
19801. More recent reports further suggest that familial aggregation may represent 
common environmental exposures such as dietary consumption patterns [Armstrong 
and Doll, 19821 in addition to a genetic component. Obesity has been identified as a 
risk factor for postmenopausal-onset breast cancer [Kirschner et al, 19811. Recent 
reports suggest a strong genetic component to obesity [Stunkard et al, 19861. 
The role of endogenous estrogens in breast carcinogenesis has been less exten- 
sively studied [Kelsey, 1979; Henderson et al, 19821. There are experimental, epide- 
miologic, and clinical data that suggest that endogenous estrogens play a crucial role. 
Experimentally, estrogens are known to be cocarcinogens in rodents [Kirschner, 
19771. Clinically, ovarian ablation influences the course of breast cancer [McGuire, 
19811. Artificial menopause by surgery or radiation substantially reduces the risk of 
breast cancer. Furthermore, the reduction of risk is greater the younger the age at 
time of artificial menopause [Feinleib, 19681. There is some evidence that exogenous 
estrogen use may increase the risk of breast cancer especially among long-term users 
and sisters of breast cancer patients [Brinton, 19841. 
Based on epidemiologic studies, hormone-mediated factors are strongly sus- 
pected of being related to breast cancer because increased risk is associated with 
events such as menarche, menopause, and first pregnancy [Pike et al, 19811. Several 
endocrine glands and their hormones appear to influence the development and func- 
tioning of breast tissue. Moreover, breast cancer does not appear prior to menarche 
or in conditions associated with ovarian dysgenesis. It is also rare in males. The 
metabolic effects of estrogen are determined by the presence of specific receptors on 
target cells that bind and retain estrogen [Stanford, et al., 19861. The epidemiology 
of estrogen receptors and breast cancer has recently been reviewed by Stanford. 
Estrogen probably effects target cells at the level of gene expression and subsequent 
protein synthesis. Multiple genetic abnormalities of estrogen metabolism are, there- 
fore, possible from increased production of estrogen in response to environmental 
studies to receptor abnormalities to oncogene stimulation to abnormal gene product. 
This paper focuses on one component and tests the hypothesis that sisters of post- 
menopausal breast cancer patient have increased sex-steroid hormone levels, estrone, 
and estradiol. The approach is different from that of recent genetic studies, [Williams, 
1984; King, 1984; Ottman, et al, 19861 that have focused on multiple case families, 
primarily young premenopausal women with very high risks within family that may 
be linked to a specific cellular genetic abnormality. The majority of breast cancer 
cases occur among postmenopausal women in which the familial association is usually 
of a much lower relative risk [Kelsey, 19791. 
Estrogens have been characterized as being necessary but not sufficient for the 
development of breast cancer [Siiteri, 19801. Others suggest an indirect role for the 
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estrogens, since they create a permissive or promotional environment for neoplastic 
transformation and growth [Brennan, 1977; Miller and Bulbrook, 19801. 
Most of the studies on endogenous estrogens have reported urinary or serum 
estrogen levels in breast cancer patients. Only one study has shown a significant 
relationship between total estradiol, nonprotein-based estradiol, and breast cancer 
[Moore et al, 19821. Part of the explanation may be owing to the difficulty in 
quantifying these hormones especially in premenopausal women. Despite the lack of 
significant results, the serum estrogen levels tended to be higher in the breast cancer 
cases although still within normal ranges [Cole et al, 1978; Drafta et al, 1980; 
McFayden et al, 19761. 
The measurement of the urinary metabolites is not as appealing an approach. 
The estriol hypothesis of breast cancer risk based on urinary measurements has lost 
support because estriol has been found to be carcinogenic in animals and the amount 
of estriol compared to the other two estrogens is very small [Kelsey, 19791. Metabolic 
studies have also questioned the role of estriol in the development of breast cancer. 
Urinary studies are difficult to conduct because many factors influence excretion 
patterns such as other illnesses, medications, and nutrition [Kirschner, 19771. 
The evidence is strong that increased blood levels of endogenous estrogens in 
postmenopausal women may be a key risk factor for breast cancer in postmenopausal 
women. The other risk factors such as family history, diet, alcohol, and obesity may 
act primarily by influencing the sex steroid hormone levels. A possible hypothesis is 
that family members are at increased risk of breast cancer because of different 
hormonal responses to environmentally related risk factors. 
METHODS 
Eighty ostensibly healthy women, 49-85 yr, were recruited for study between 
October 1983 and May 1984. All women were Caucasian. Forty of these women were 
sisters of women with histologically confirmed breast cancer, postmenopausal onset. 
The remaining women, matched individually on age ( 5  10 yr), served as healthy 
controls. The choice of unaffected family members of breast cancer patient reduces 
the concern that results may have been influenced by the cancer rather than antecedent 
to its development. Seventy-five percent of the controls were recruited through 
friendship networks, the remainder through community or extended family sources. 
Biochemical confirmation of postmenopausal status for each participant was deter- 
mined by follicle-stimulating hormone (FSH) levels in excess of 30 MIU/dl [Nordin 
et al, 19811. There were, therefore, 39 pairs available for matched pair analysis. 
After obtaining written informed consent, data were obtained through home 
interviews. All home interviews were conducted between 8 am and 11 am. Inter- 
viewer-administered questionnaires on reproductive, personal, and family medical 
histories, demographic information, and dietary intake were obtained. Personal med- 
ical histories included questions on current medication use and within the 6 mo prior 
to interview. Dietary intake was obtained through the use of a continuous 3-day food 
record. The interviewer instructed each participant in the recording of dietary intake 
and documented each record after it was returned. A registered dietician, blinded to 
the study status of the participant, entered all food record data via a computerized 
data bank, which utilized the Agricultural Handbook, Number 456 [Agricultural 
Research Service, 19751. A report on the dietary intake oi  these women is under 
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review [Begg et al, 19871. Anthropometric measurements were obtained using a 
standardized protocol [National Center for Health Statistics, 19781. A fasting blood 
specimen was obtained for lipoprotein and sex steroid hormone determinations. Each 
blood specimen was allowed to clot at room temperature and then maintained on ice 
until processed in the laboratory. All serum was stored in a minus 70°C freezer in 4- 
ml aliquots until the analyses were performed. The blood specimens for the sisters 
and their matched controls were obtained within a few days of one another. These 
specimens were stored in the same Ultrafreezer and analyzed within the same batches. 
Lipid and sex-hormone analysis were run blindly, ie, the technicians were not aware 
of the study status of the participants. Lipoprotein levels were analyzed in a central 
laboratory that was monitored by the US Centers for Disease Control Standardization 
program. 
Serum estrone and estradiol concentrations were measured on the same serum 
sample following extraction, LH-20 Sephadex column chromatography and radioim- 
munoassay (RIA) using a specific antibody [Radfar et al, 1976; Korenman et al, 1974; 
Cauley et al, 1986al. The column chromatography gives complete separation between 
estrone, estradiol, and estriol. A small amount of radioactivity was added to each 
sample prior to extraction. The recovery of the radioactivity was used to adjust each 
sample for procedural losses during extraction and subsequent chromatography. The 
concentration of steroid in the appropriate column eluate was measured in triplicate. 
If there was greater than 10% variation of the triplicates, a repeat extraction, chro- 
matography and RIA was performed. The estrone antibody was purchased from 
Endocrine Sciences and the estradiol antibody obtained from Dr. Gordon Niswender. 
Three portions of the estrone column eluate were used in the RIA. Since the concen- 
tration of estradiol was much lower, only a single portion of the estradiol column 
eluate was used in the RIA. Each assay set contained duplicates of the quality control 
plasma. The within (intra) assay coefficient of variation of estrone and estradiol was 
12% and 11 %. The between assay variation was 6% and 16%, respectively. 
Serum testosterone and androstenedione were measured on the same serum 
sample following extraction, LH-20 Sephadex column chromatography and (RIA) 
using a specific antibody [deLacerda et al, 1973; Carr et al, 1971; Gutai et al, 19811. 
The column chromatography gave complete separation between testosterone, andros- 
tenedione, and dihydrotestosterone. Each assay set included duplicate samples of the 
quality control pool. The within (intra) assay coefficient of variation for testosterone 
and androstenedione was 9% and 11 % respectively. Blood used to prepare a large 
quality control pool was obtained from healthy volunteers and handled in the same 
way as the study samples. At the conclusion of the study, the results of the determi- 
nations of the quality control serum were reviewed. For all of the hormones measured 
there was no significant difference in the quality control serum at the beginning or 
conclusion of the study. This would indicate that there was no significant effect of 
prolonged freezing on the concentration of the hormones. Additionally, the results of 
the quality control samples were divided into four time periods and there was no 
significant difference between the means of the four time periods and the mean of the 
entire study set. 
In addition, ten blinded replicates from study participants were used to evaluate 
interassay variability. The variation within individuals for the ten “dummy” results 
was 12% (SE 1.5) of the original results. 
The evaluation of biological variability for serum estrone levels in postmeno- 
pausal women from this laboratory found the interindividual variability to be five 
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times greater than the laboratory variability [Cauley et al, 1986al. More importantly, 
there were neither significant biologic variability nor significant interaction over the 
four week period. These results suggest that a single measurement for estrone is 
reliable in characterizing a postmenopausal women for epidemiologic research at a 
single point in time. 
Data analysis included descriptive statistics, univariate and multivariate statisti- 
cal packages developed by SPSS [Hull and Nie, 19811 and BMDP [Dixon, 19851. 
RESULTS 
Group Data 
The distribution by group of age, height, weight, body mass index, serum 
estrone, estradiol, and lipoproteins for the 39 siblings and 40 controls are shown in 
Table I. Fewer siblings were married or were ever pregnant. A greater proportion of 
siblings reported ever having smoked cigarettes compared with the controls. For the 
subset of women who reported a natural menopause (N=50), the mean ages were 
49.2 4 .9  for the siblings and 48.3 k 4.0 for the controls. Mean years since natural 
menopause was 13.1 yr and 13.3 yr for the siblings and controls, respectively. An 
additional 29 participants underwent a surgical menopause. For the 13 siblings, the 
mean age was 45.5 yr and for the 16 controls 45.6 yr. Mean years since surgical 
menopause for the siblings was 17.9 yr and for the controls 16.8 yr. Body mass index 
(BMI) was calculated using weight divided by height squared. Mean weight was 4.3 
kg (or 9.5 lbs) greater in the siblings compared to the controls. Median weight was 
also higher in the siblings versus the controls (69.9 vs 61.5 kg). Mean height was 
comparable so the higher BMI observed in the siblings was owing to their excess 
weight levels compared to the controls. 
Both total cholesterol and high-density lipoprotein cholesterol levels were non- 
significantly lower in the siblings compared to the controls (Table I). 
Serum estrone, the predominant estrogen in postmenopausal-aged women, was 
found to be significantly higher, 58.9 vs 47.8 pg/ml, in the siblings compared to the 
controls (Student’s t test, one-tail, P=0.005). For the subset of women (N=59) for 
whom there was sufficient serum for estradiol measurements, the siblings had signif- 
icantly higher levels than the controls, 7.9 vs 5.4 pg/ml, P=O.O4. 
The frequency distribution for serum estrone by group reveals that at a level of 
less than 50 pg/ml of estrone, fewer siblings (45% vs 62.5%) are represented; 
between 50-69 pg/ml of estrone, the distributions are equal and above 70 pg/ml of 
estrone 23% of the siblings are represented compared to 5% of the controls. The 
median serum estrone level of the siblings was 57.0 pg/ml and 45.6 pg/ml for the 
controls. 
The paired serum estrone differences were computed by subtracting the absolute 
estrone value of the control from the estrone value of her matched sibling. The range 
of differences went from a - 52.9 to + 73.0. There were eight pairs with negative- 
estrone difference (sibling - control, Table 11). There were 30 positive-estrone differ- 
ence pairs and one pair with equivalent estrone levels so that the paired difference 
was less than 1 pg. Eighteen of the thirty positive-estrone difference pairs recorded 
less than a 20 pg difference. The remaining 12 paired differences ranged from 21.2 
to 73.0 pg. The mean relative difference was 10.8 with a standard error of 4.1 
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TABLE 11. Distribution of Paired Serum Estrone Differences 
Interval difference 
sibling-control Number of sibling- 
estrone (pg/ml) control pairs 
< -11 5 





2 40 3 
Mean relative difference (sibling-control) 10.8 
Standard error 4.1 
TABLE 111. Univariate Correlation Coeffkents of Serum Estrone With Selected Variables by 
Group* 
Sibling Control 
Selected variables r P r P 
Weight 0.39 0.007 0.57 0.00 
Body mass index 0.34 0.01 0.55 0.00 
Total cholesterol -0.24 0.07 0.00 0.49 
LDL cholesterol -0.33 0.02 -0.10 0.27 
Total HDL cholesterol -0.16 0.15 -0.05 0.39 
HDL-2 cholesterol -0.13 0.21 0.00 0.49 
HDL-3 cholesterol -0.12 0.22 0.03 0.42 
Total triglycerides 0.13 0.20 0.14 0.19 
*HDL = high density lipoprotein; LDL, low density lipoprotein; body mass index = weightlheight’. 
Statistically significant associations were observed for weight and Body Mass 
Index (BMI) in each group and serum estrone levels. These correlations were higher 
in the control group compared to the siblings. There was a stronger inverse relation- 
ship between low-density lipoprotein cholesterol and serum estrone in the sibling 
group (Table 111). The relationship between high-density lipoprotein cholesterol levels 
and serum estrone was not significant. 
To evaluate further the determinants of serum estrone, multiple regression 
analyses were performed using both the absolute serum estrone levels and the 
logarithmic-transformed values. The results were similar. 
The independent variables used were age, study status (sibling or control), 
current smoker (yesho), and current weight (kg). Current weight, rather than BMI, 
was used because height was comparable in each group, making weight a better direct 
measure of ponderosity. Both study status and current weight were found to be 
statistically significant. In both analyses, current weight was highly significant, with 
a P value of less than O.OOO1 and for study status, P=O.O3. The regression coefficient 
for study status was negative because serum estrone levels were higher in siblings 
than controls (Table IV). The results were similar if BMI was used instead of current 
weight. 
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TABLE IV. Multiple Regression Analysis of Determinants of Serum Estrone Levels (N=79) 
Standard regression 
Coefficient SE coefficient P (2 tail) 
Age -0.02222 0.27639 -0.008 0.9361 
Study statusa -8.44069 3.91967 -0.219 0.0345 
Current smoker 3.15103 5.02337 0.067 0.5324 
Current weight 0.59208 0.14010 0.440 O.OOO1 
aStudy status defined as siblings or controls. 
TABLE V. Summary Distribution of Paired Weight and Estrone Differences 
Sibling estrone levels 
Paired weight Number greater than control 
difference of weight levels (positive-estrone 
categories pairs differences) Percent 
Sibling = control 3 2 66.6 
Sibling < control 15 8 60.0 
Total pairs 39 30 76.9 
Sibling > control 21 20 95.3 
Matched Pairs Analysis 
Body weight is a known determinant of serum estrone levels [Siiteri et al, 1976; 
Judd et al, 19761. Matched pairs analyses were performed to adjust for weight so that 
the nonweight mediated influence could be better quantified. The adjustment was 
necessary because weight, which is a continuous variable, was discordant within the 
pairs. Thirty-nine pairs were available for the three methods of matched pairs 
analysis: 1) nonparametric ranking of the paired differences, 2) analysis of residual 
estrone levels, and 3) calculations of weight-adjusted serum estrone differences. 
There were no differences in height between cases and controls. Weight differences 
were, therefore, used rather than BMI. 
Nonparametric Ranking 
The distribution of paired estrone differences in relationship to paired weight 
differences was created by first ranking the individual paired differences for weight 
from the most extreme negative values where the sibling was lighter than her matched 
control to the most positive value when the sibling registered a much higher weight 
than her control. 
There were 15 negative-weight pairs (sibling -control) and twenty one positive- 
weight pairs (Table V). Three pairs in which the sibling and her control were 
essentially equal weights, registered a paired-weight difference of less than 1 kg . 
Using a ranking of the paired weight differences, there were 8 negative-estrone pairs 
and 30 positive-estrone pairs. One pair had equivalent estrone levels. 
When the two distributions are combined employing the ranking based on the 
paired weight differences, 8 of the 15 negative-weight pairs exhibit positive-estrone 
differences. Twenty of the twenty one positive-weight pairs exhibited positive-estrone 
differences. Two of the three equal-weight pairs showed positive-estrone differences 
and one showed a negative-estrone difference. Thus compared with the match but 
controlling for weight, 8 of the 15 siblings still had higher estrone levels even in 
situations where the control weighed more than the sibling. 
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Analysis of Residual Estrone Levels 
For the second method of paired analysis, scatter plots of the absolute estrone 
and weight levels were obtained for all 79 participants and for the 40 controls alone. 
The two approaches were used to minimize the possible bias of calculating residual 
estrone values based solely on the control group. The distribution of paired residual 
estrone levels using the absolute estrone levels as compared to the estimated estrone 
levels for her specific weight in both equations revealed very similar results (Table 
VI). Using the controls only equation, there were 15 negative-estrone difference 
pairs, where the sibling had a lower residual estrone level than her control. There 
were 14 negative-estrone difference pairs with the N =79 equation. A matched paired 
difference t test was performed comparing the residual estrone value in case versus 
matched control. The difference was statistically significant, P =0.02 level. The 
Wilcoxan matched pair signed rank test (one-tail) was also found to be statistically 
significant using both the N =79 equation (P=0.009) and the N =40 equation 
(P =0.002). 
Weight-Adjusted Serum Estrone Difference 
The third method employed to adjust the serum estrone levels by weight was 
completed by using the actual serum estrone level (pg/ml), divided by the individual 
weight (in kg). Paired estrone differences, now adjusted by weight, were obtained for 
each of the sibling-control pairs. The distribution of these paired estrone differences 
was similar to Table V, shown earlier, which calculated the absolute estrone differ- 
ences using a weight ranking. The weight-adjusted calculation resulted in a downward 
shift in the paired values. Fifteen of thirty nine pairs were estrone negative from the 
residual analysis (Table VI) compared to 8/39 pairs in Table V where no weight 
adjustment was made. 
Although the principle sex-steroid hormone in postmenopausal women is es- 
trone, the levels of estradiol may be important. The levels of estradiol were signifi- 
cantly higher in the siblings, 7.9 pg/ml as compared to the 5.4 p g / d  for the controls, 
P=O.O4 (Table I). There was, unfortunately, not enough serum available for the 
measures of estradiol in all subjects and the matched pairs could not be done. The 
estradiol levels were highly correlated with estrone levels and also with body weight 
and body mass index (Table VII). This was true for both cases and controls. 
Estrone is not bound to sex-hormone binding globulin, while estradiol is bound 
[Siiteri et al, 19821. The amount of free estradiol in postmenopausal women is 
TABLE VI. Summary Table for Analysis of Residual Estrone Levels 
N=79: Y=21.497 + 0.6225 X X 
Sibling > control Sibling < control 
Paired 
Estrone 25 14 
Differences 
N=40: Y=1.6652 + 0.72930 x X 
Sibling > control Sibling < control 
Paired 
Estrone 24 15 
Differences 
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Serum estrone 0.57 0.00 0.40 0.01 
Weight 0.54 0.001 0.35 0.03 
BMI” 0.49 0.002 0.35 0.03 
“Body mass index, weight/height2. 
extremely low, probably less than 1 pg/ml [Siiteri et al, 19861 and cannot be reliably 
measured in these postmenopausal women. Even if the free estradiol is a much more 
potent estrogen than estrone it is probably unlikley that the less than 1 pg levels as 
compared to the almost 50 pg levels of estrone would contribute substantially to the 
total estrogen effect. 
Serum testosterone and androstenedione were also measured. The androstene- 
dione levels were 111.11 ng/dl in the 35 siblings (SD 41.5) and 92.83 (SD 38.6) in 29 
controls (P =0.07). The androstenedione levels were significantly correlated with the 
estrone levels for both the siblings and controls. 
The mean testosterone levels were 54.9 ng/dl (SD 39.9) in 35 siblings and 
38.55 (SD 24.9) for 29 controls (P=0.05). The testosterone levels were highly 
correlated with estradiol levels for both siblings and controls but not with the estrone 
levels. The “free” testosterone levels were not measured. 
DISCUSSION 
Excess body weight is known to be a risk factor for breast cancer [Kelsey, 1979; 
Krischner et al, 1982; Paffenbarger et al, 19801, and as expected the siblings weighed 
more than their matched controls. Using group statistics, the mean body weight of 
the siblings are 4.3 kg more than the control group. The siblings also had a higher 
median weight than the controls. On matched-pairs analysis, 20 of 21 sibling-control 
pairs recorded excess weight differences (Table 11). Thirty of the 39 sibling-control 
pairs have higher serum estrone levels (Table V). When the two distributions are 
combined, adjusting for weight, 20/21 excess weight pairs also record higher estrone 
levels in siblings versus controls (Table V). Some of the negative-weight pairs (sibling 
weighs less than her control) have higher estrone levels in the siblings. We did further 
analysis to evaluate these individuals. 
In Figure 1, the degree of obesity is compared with estrone levels. Based on 
current knowledge about estrogen metabolism, participants who fall within quadrants 
I and IV demonstrate the expected biological relationships. That is, women who are 
leaner should have lower estrone levels than more obese women. It is the women 
who fall within quadrants I1 and 111 who deviate from the expected biological 
relationships. From what we know about breast carcinogenesis, women in quadrant 
I1 are the most important to evaluate. These participants exhibit high estrone levels 
even though they are relatively lean. Seven of the ten participants in quadrant I1 are 
siblings of breast cancer patients. This finding lends further support to the hypothesis 
that the potential increased risk of breast cancer in postmenopausal siblings may be a 
function of their higher estrogen levels in response to environmental stimuli such as 
obesity, diet, and alcohol. 
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The results of this study represent the first time that higher estrone and estradiol 
levels have been measured in siblings of postmenopausal breast cancer patients. Such 
an observation may represent an important link in our understanding of the relation- 
ship between genetic and environmental risk factors for breast cancer. The genetic 
component to breast cancer etiology may be a function of either higher estrogen levels 
in the sisters of breast cancer patients at similar environmental exposures or perhaps 
to the greater sensitivity of the breast tissue to these estrogen levels. Genetic factors 
are more important with earlier onset of breast cancer [King et al, 1985; Lynch, 1980; 
Knudson, 19731. However, other investigators have documented a substantial genetic 
contribution to the onset of postmenopausal breast cancer [Ottman et al, 1983, 
Henderson et al, 1974; Burns et al, 1981; Hislop et al, 1986; Ottman, 19861. 
These estrogen differences are even more impressive given the comparability 
of the women on a large number of factors that may influence endogenous hormone 
levels. The siblings and their matched controls are remarkably similar in their 
ethnicity, age, reproductive and medical histories, years of education, and social 
class. The reported dietary intake is also similar at least based on analysis of 3-day 
food records on a subset of 30 pairs. Prior and current medication use between the 
groups is comparable. Blinded replicates for the estrone analysis were included and 
laboratory variability was found to be minimal. In general, our estrone and estradiol 
results are within the range of recent reports in the literature [Jensen et al, 1985; 
Lesko et al, 19851. 
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Furthermore, our hormone results have remained comparable across multiple 
studies completed within the last 3 years [Cauley et al., 1986a,b]. Studies performed 
on blood stored for many years showed significant differences in free estradiol 
concentrations between breast cancer cases and controls [Siiteri et al, 19811. How- 
ever, a subsequent study by the same group using blood stored for much shorter 
periods of time found no differences [Siiteri et al, 19861 and suggests that with 
prolonged storage there may have been a differential increase in the free estradiol in 
cases compared to controls. Our blood specimens (for both siblings and controls) 
were stored at -70 “C and measured within 1 yr. 
A recent review of the relationship between estrogens and breast cancer note 
that in four of the five case-control studies, estradiol levels have been higher in the 
breast cancer cases than in the controls; one study in Holland did not confirm this 
relationship [Bulbrook et al, 19861. 
This same report gave updated findings from a prospective study [Bulbrook et 
al, 19861. There were only six postmenopausal cancer patients in the study and 
therefore it is very difficult, if not impossible, to evaluate the relationship between 
the hormone levels and subsequent risk of breast cancer. Overall, including predom- 
inantly the premenopausal patients, the free and albumin-bound estradiol levels 
appeared to be higher in the cases as compared to their matched controls. However, 
the entire study has only 16 cancer patients. The authors [Bulbrook et al, 19861 note 
that “it must be admitted that the role of protein binding of steroids and modulating 
their biological activity is not understood. Availability of protein bound hormones, 
varies from organ to organ and from species and species. At the moment the simple 
concept of non-protein bound estradiol and albumin bound estradiol are available for 
biological activity on normal and neoplastic breast tissue fits well with the limited 
data that has been obtained so far. Thus, the situation with regard to estrone, estradiol 
and free albumin bound estradiol in the postmenopausal women is far from clear. ” 
In postmenopausal women, much of the estradiol is derived from estrone and 
clearly an almost 100-fold difference between estrone and free estradiol in the blood 
suggests the possibility the estrone may be playing an important role in breast cancer 
risk in postmenopausal women. Estrone sulfate and other metabolities of estrogen 
may also be important in the etiology of breast cancer [Santner et al, 1984; Prost et 
al, 19841. 
The estrone levels can clearly be shown to have physiological importance. A 
direct relationship has been demonstrated between endogenous estrone levels and 
bone density among postmenopausal women even after adjusting for body weight 
[Cauley et al, 1986al. The estrone levels of the siblings of breast cancer patients are 
inversely related to low-density lipoprotein cholesterol. Thus, we think the postmeno- 
pausal levels of estrone are possibly related to three important diseases of postmeno- 
pausal women: osteoporosis, cardiovascular disease, and breast cancer risk. The 
major source of estrone in the postmenopausal women is from the aromatization of 
the adrenal steroid androstenedione, which occurs primarily in fat but also in muscle 
and other tissues. The androstenedione levels were higher in siblings than controls. 
Whether the increase in androstenedione is primarily responsible for higher estrone 
and estradiol levels in the siblings is unknown. As previously noted, the degree of 
obesity may also be partially influenced by genetic factors. 
The results, although unique, are still based on a small sample. They do provide 
some evidence for a possible link between diet, obesity, hormones, genetic factors, 
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and breast cancer. Obesity and possibly high fat or high caloric intake could result in 
elevated estrone and estradiol levels in postmenopausal women, primarily by increas- 
ing aromatization in adipose tissue, and possibly muscle tissue of androstenedione to 
estrone [Santen, 19821. The degree of sensitivity to these evironmental stimuli may 
be at least partially genetically determined. The genotypic expression would therefore 
be the hormone levels. The relatively low order familial association of breast cancer 
is therefore probably due to the interrelationship of the environmental and the genetic 
determinants of the hormone levels and the response of breast tissue, the phenotypic 
expression. 
Current and future prospective studies may delineate the specific relationships 
of endogenous hormone levels to breast cancer risk. These studies will need to 
measure both the hormone levels as well as metabolities such as estrone sulfate. The 
efficacy of specific dietary manipulations could then be evaluated in relationship to 
specific changes in hormonal parameters as well as in the risk of breast cancer. There 
is a continuing and important need to determine the specific effects of various 
environmental changes on endogenous hormone levels especially in both pre- and 
post-menopausal women. Such studies should evaluate the effects of specific dietary 
manipulations as well as caloric restriction and weight change. The combination of 
well controlled environmental manipulation and genetic studies in order to quantify 
changes in probable biochemical precursors of breast cancer offers the best approach 
to understanding the etiology of this disease. 
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